Rather than producing medicines through batch-wise, step-by-step processes, CONTINUUS Pharmaceuticals offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals. The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs.
CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT and Novartis on Continuous Manufacturing. We specialize in end-to-end Integrated Continuous Manufacturing (ICM), with the application of novel process technologies that enable rapid production of pharmaceuticals at significantly reduced costs and better quality. With ICM, we will improve affordability and accessibility of pharmaceuticals on a global scale.
September 5, 2019
CONTINUUS Pharmaceuticals Raises $5 M in Series B Round, Led by Mark Bamforth Who Will Join the Board of Directors
August 22, 2019
Hiring Flow Chemist and Analytical Chemist
May 15, 2019
CONTINUUS featured in CDER Impact Stories
